If this message is not displayed correctly, click here.
|
|
ERA-EDTA FLASH is the official ERA-EDTA E-NEWSLETTER
No 162, October 2018
|
|
Editor in Chief: María José Soler Romeo
Editorial Secretariat: Valentina Cocchi, Francesca Trebelli
Newsletter Design: Ilaria Martini
ERA-EDTA Headquarters - Via XXIV Maggio, 38 - 43123 Parma - Italy
|
|
|
|
Join The challenge of osteoporosis in CKD educational event organised by EUROD, a CKD-MBD Working Group initiative, in collaboration with the International Osteoporosis Foundation (IOF) to be held on January 18, 2019 in Leuven (Belgium). Updates on the clinical assessment and treatment of osteoporosis in CKD anno 2019 will be presented through state of the art lectures by key opinion leaders and interactive (with voting system) discussions.
Click here to download the full programme.
Click here to register.
|
|
The ERA-EDTA Working Group on Inherited Kidney Diseases (WGIKD) and ERKNet, the European Reference Network for Rare Kidney Diseases are happy to present Rare Kidney Disease Webinars, an educational initiative that is freely accessible to all users.
A new Webinar will be held on TUESDAY, November 6, 2018 at 4:00-5:00 pm CET (3:00 pm UK time, 5:00 pm Eastern European time).
Rachel Lennon (Manchester, UK) will present on ‘Microscopic Haematuria'.
Register here to receive the access link to the Webinar.
Please pay attention to the technical requirements provided with the access link.
If you would like to be notified automatically about future Rare Kidney Disease Webinars, please sign up here for the ERKNet Newsletter.
You can find the schedule for upcoming Webinars and past presentations at www.erknet.org under the ‘Education & Training’ tab.
|
|
Tolvaptan offers hope to those with polycystic kidney disease and is the first treatment to slow kidney growth and eGFR decline. However, there is a not insignificant side effect burden and ongoing debate concerning when to initiate and when to cease therapy. These two papers debate the pros and the cons of tolvaptan use in polycystic kidney disease.
Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease versus Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers?
The papers are accessible free of charge until this Sunday at 23.59 (UK time). Do not miss them!
|
|
Don’t miss important information on the next ERA-EDTA congresses, important deadlines for the 56th ERA-EDTA Congress in Budapest, Council vacancies and more!
Read more→
|
|
Help us donate to the European Kidney Health Alliance!
While you settle your membership fee, you may choose to add a small amount, which will be donated to EKHA: this extra fee is used exclusively to support the activities of EKHA.
Thank you for your support!
|
|
|
|
|
|
|
|
|
|
|
|
|
Initiatives
|
|
Working Groups
...and their latest initiatives:
|
|
Committees...
|
|
|
|
The advantages of being a member of ERA-EDTA
As a member you will become part of one of the
most influential European Medical Associations!
|
|
The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.